Study data sends Incyte shares lower

Shares of Incyte dropped 15 percent Monday after the company released data from a mid-stage trial of Reverset, its once-a-day pill for treating HIV. The Wilmington, Delaware-based company said 54 percent of patients taking Reverset along with standard HIV drugs saw more than a 90 percent drop in the amount of the virus in their bloodstream after four months of treatment. That compared with 40 percent of those who experienced a similar drop in the virus after receiving a placebo along with their standard HIV treatment. The company said it plans to move ahead with Phase III trials later this year.

- read this AP story for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.